Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
178
-
Total 13F shares, excl. options
-
104M
-
Shares change
-
+6.56M
-
Total reported value, excl. options
-
$326M
-
Value change
-
+$18.1M
-
Put/Call ratio
-
0.43
-
Number of buys
-
77
-
Number of sells
-
-79
-
Price
-
$3.14
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q4 2022
217 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q4 2022.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 178 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 104M shares
of 295M outstanding shares and own 35.27% of the company stock.
Largest 10 shareholders include BlackRock Inc. (15.4M shares), VANGUARD GROUP INC (14M shares), WASATCH ADVISORS INC (12.7M shares), STATE STREET CORP (9.79M shares), CREDIT SUISSE AG/ (3.81M shares), DIMENSIONAL FUND ADVISORS LP (3.44M shares), Nuveen Asset Management, LLC (3.33M shares), Rokos Capital Management LLP (3.03M shares), Avidity Partners Management LP (2.75M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.49M shares).
This table shows the top 178 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.